Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186617 | 0.88 | KMT2A (0.59) | GRM5KMT2AABCG2L3MBTL1CYP1A2 | |
| SCHEMBL2019360 | 0.84 | EGFR (0.55) | GRM5KMT2AKCNH2SCN9AABCG2 | |
| SCHEMBL2823612 | 0.83 | SLC2A1 (0.57) | GRM5KMT2AL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2019268 | 0.81 | KMT2A (0.65) | GRM5KMT2AABCG2L3MBTL1CYP1A2 | |
| SCHEMBL5486449 | 0.78 | KMT2A (0.81) | KMT2AKCNH2L3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL9489007 | 0.76 | L3MBTL1 (0.65) | GRM5KMT2AL3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL29850051 | 0.76 | NPC1 (0.60) | KMT2AKCNH2SCN9AALDH1A1KDM4E | |
| SCHEMBL21258999 | 0.76 | NPC1 (0.60) | KMT2AKCNH2SCN9AALDH1A1KDM4E | |
| SCHEMBL2885850 | 0.75 | CDK2 (0.49) | KMT2AKCNH2SCN9AL3MBTL1CYP1A2 | |
| SCHEMBL5475320 | 0.75 | FFAR1 (0.56) | KMT2ATDP1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | claimed |
| EP-2066655-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-06-10 | — | — | EP | claimed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | claimed |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| EP-2066655-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | KCNJ2, KCNN2, KCNN1 | GRM5 483/4885KMT2A 1374/4885KCNH2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.